Email this article 
The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta‑Analysis
Abstract
Background: Fingolimod and interferons are used in the relapse form of multiple sclerosis (MS). The goal of this systematic review and meta‑analysis was to evaluate the efficacy of fingolimod versus interferon in patients with MS. The systematic search was done in PubMed, Scopus, Embase, Web of Science, and Google Scholar. Methods: The references of included studies as well as conference abstracts were searched up to July 2021. The literature search revealed 8211 articles, and after deleting duplicates 5594 remained. For the meta‑analysis, four studies were included. The standardized mean difference (SMD) of the Expanded Disability Status Scale (EDSS) after treatment (interferon vs fingolimod) was −0.06 (95% CI: −0.28, 0.17) (I2 = 80.2%, P = 0.002). Results: The SMD of the annual relapse rate (ARR) after treatment (interferon – fingolimod) was −0.08 (95% CI: −0.53, 0.36) (I2 = 95.5%, P < 0.001). The SMD of the ARR after treatment and before treatment in the interferon group was − 1.45, (95% CI: −1.55, −1.36) (I2 = 0, P = 0.3). The SMD of ARR after treatment and before treatment in the fingolimod group was − 1.3, (95% CI: −1.94, −0.65) (I2 = 97.4%, P < 0.001). Conclusions: The results of this systematic review show that efficacy of interferon and fingolimod in controlling relapse rate and disability is similar.
International Journal of Preventive Medicine 14():131, December 2023. | DOI: 10.4103/ijpvm.ijpvm_12_22
Corresponding Author: Dr. Mahsa Ghajarzadeh
E‑mail: m.ghajarzadeh@gmail.com
You can also search for this author in: PubMed Google Scholar
Keywords
Full Text:
PDFReferences
Azimi A, Doosti R, Samani SMV, Roostaei B, Gashti SH,
Navardi S, et al. Psychometric properties of the persian version
of the PARADISE‑24 questionnaire. Int J Prev Med 2021;12:50.
Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV,
Ghajarzadeh M. Effect of vitamin D supplements on relapse
rate and expanded disability status scale (EDSS) in multiple
sclerosis (MS): A systematic review and meta‑analysis. Int J
Prev Med. 2021;12:42.
Koriem KMM. Multiple sclerosis: New insights and trends.
Asian Pac J Trop Biomed 2016;6:429‑40.
Moosazadeh M, Nabinezhad‑Male F, Afshari M, Nasehi MM,
Shabani M, Kheradmand M, et al. Vitamin D status and
disability among patients with multiple sclerosis: A systematic
review and meta‑analysis. AIMS Neurosci 2021;8:239‑53.
McKay KA, Kwan V, Duggan T, Tremlett H. Risk factors
associated with the onset of relapsing‑remitting and primary
progressive multiple sclerosis: A systematic review. BioMed Res
Int 2015;2015. doi: 10.1155/2015/817238.
Derwenskus J. Current disease‐modifying treatment of multiple
sclerosis. Mt Sinai J Med 2011;78:161‑75.
Boster A, Nicholas J, Wu N, Yeh W‑S, Fay M, Edwards M,
et al. Comparative effectiveness research of disease‑modifying
therapies for the management of multiple sclerosis: Analysis
of a large health insurance claims database. Neurol Ther
;6:91‑102.
Foster CA, Howard LM, Schweitzer A, Persohn E,
Hiestand PC, Balatoni B, et al. Brain penetration of the oral
immunomodulatory drug FTY720 and its phosphorylation in
the central nervous system during experimental autoimmune
encephalomyelitis: Consequences for mode of action in multiple
sclerosis. J Pharmacol Exp Ther 2007;323:469‑75.
Coelho RP, Payne SG, Bittman R, Spiegel S, Sato‑Bigbee C.
The immunomodulator FTY720 has a direct cytoprotective
effect in oligodendrocyte progenitors. J Pharmacol Exp Ther
;323:626‑35.
Signoriello E, Landi D, Monteleone F, Saccà F, Nicoletti CG,
Buttari F, et al. Fingolimod reduces the clinical expression of
active demyelinating lesions in MS. Mult Scler Relat Disord
;20:215‑9.
Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A,
Capkun G, et al. Comparative effectiveness of fingolimod versus
interferons or glatiramer acetate for relapse rates in multiple
sclerosis: A retrospective US claims database analysis. Curr Med
Res Opin 2013;29:1647‑56.
Ernst FR, Barr P, Elmor R, Wong SL. Relapse outcomes,
safety, and treatment patterns in patients diagnosed with
relapsing‑remitting multiple sclerosis and initiated on
subcutaneous interferon β‑1a or dimethyl fumarate: A real‑world
study. Curr Med Res Opin 2017;33:2099‑106.
Bowen JD, Kozma CM, Grosso MM, Phillips AL. A real‑world
comparison of relapse rates, healthcare costs and resource
use among patients with multiple sclerosis newly initiating
subcutaneous interferon beta‑1a versus oral disease‑modifying
drugs. Mult Scler J Exp Transl Clin 2018;4:2055217318819031.
doi: 10.1177/2055217318819031.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D,
Oxman AD, et al. The cochrane collaboration’s tool for assessing
risk of bias in randomised trials. BMJ 2011;343:d5928. doi:
1136/bmj.d5928.
Martinez ARC, Correale J, Coyle PK, Meng X, Tenenbaum N.
Efficacy and safety of fingolimod in Hispanic patients with multiple
sclerosis: Pooled clinical trial analyses. Adv Ther 2014;31:1072‑81.
Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P,
et al. Efficacy of fingolimod and interferon beta‑1b on
cognitive, MRI, and clinical outcomes in relapsing–remitting
multiple sclerosis: An 18‑month, open‑label, rater‑blinded,
randomised, multicentre study (the GOLDEN study). J Neurol
;264:2436‑49.
Cohen JA, Barkhof F, Comi G, Hartung H‑P, Khatri BO,
Montalban X, et al. Oral fingolimod or intramuscular interferon
for relapsing multiple sclerosis. N Engl J Med 2010;362:402‑15.
Askari M, Mirmosayyeb O, Ghaffary EM, Ghoshouni H,
Shaygannejad V, Ghajarzadeh M. Incidence of cancer in patients
with multiple sclerosis (MS) who were treated with fingolimod:
A systematic review and meta‑analysis. Mult Scler Relat Disord
;59:103680. doi: 10.1016/j.msard. 2022.103680.
Bouscary A, Quessada C, Rene F, Spedding M, Turner BJ,
Henriques A, et al., editors. Sphingolipids metabolism
alteration in the central nervous system: Amyotrophic lateral
sclerosis (ALS) and other neurodegenerative diseases. Semin
Cell Dev Biol 2021;112:82‑91.
Kappos L, Radue E‑W, O’Connor P, Polman C, Hohlfeld R,
Calabresi P, et al. A placebo‑controlled trial of oral fingolimod in
relapsing multiple sclerosis. N Engl J Med 2010;362:387‑401.
Patti F. Optimizing the benefit of multiple sclerosis therapy: The
importance of treatment adherence. Patient Preference Adherence
;4:1‑9. doi: 10.2147/ppa.s8230.